Eli Lilly (NYSE:LLY) is preparing to file for regulatory approval of its investigational weight-loss medication, orforglipron, in several key markets in rapid succession, according to the company’s international president, Patrik Jonsson.
“We are submitting to most of the major regulatory bodies pretty much at the same time,” Jonsson told Reuters.
The filings will target authorities in the United States, the U.K., the European Union, Japan, and China, following a coordinated timeline. Additional submissions are planned for regulators in the United Arab Emirates and Saudi Arabia.
This simultaneous global filing strategy aims to position Eli Lilly competitively in the growing obesity-treatment sector, where it faces rivals such as Novo Nordisk.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.